Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HRAS | P01112 | 4/20 | 0.38 |
| ▸ | ESR1 | P03372 | 4/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.38 |
| ▸ | TOP1 | P11387 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | HPSE | Q9Y251 | 5/20 | 0.36 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20796574 | 0.98 | HDAC1 (0.42) | HDAC1HDAC2HDAC8HRASESR1 | |
| SCHEMBL20796134 | 0.87 | HDAC1 (0.44) | HDAC1HDAC2HDAC8HRASESR1 | |
| SCHEMBL19636637 | 0.84 | TOP1 (0.41) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL26440371 | 0.84 | HDAC1 (0.41) | HDAC1HDAC2HDAC8HRASESR1 | |
| SCHEMBL19636634 | 0.78 | HRAS (0.36) | HRASESR1ESR2TOP1KDM4E | |
| SCHEMBL10110776 | 0.77 | RPS6KA2 (0.31) | RPS6KA2 | |
| SCHEMBL25857771 | 0.76 | HDAC1 (0.46) | HDAC1HDAC2HDAC8HRASESR1 | |
| SCHEMBL19636927 | 0.76 | HDAC1 (0.46) | HDAC1HDAC2HDAC8HRASESR1 | |
| SCHEMBL10110767 | 0.76 | AR (0.35) | HRASESR1ESR2TOP1HPSE | |
| SCHEMBL22363485 | 0.75 | HDAC1 (0.47) | HDAC1HDAC2HDAC8HRASESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | MERSANA THERAPEUTICS, INC. (US) | 2023-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11638760-B2 | Pyrrolobenzodiazepine antibody conjugates | GABRA4, GABRA1, GABRA2 | HDAC1 1552/4885HDAC2 1086/4885HDAC8 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.